Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + progesterone
- Development stage
- Unknown
- Lead developer
- Li Ning
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Toripalimab (Tuoyi) is a recombinant, humanized IgG4 monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor. Developed by Shanghai Junshi Bioscience, it functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, thereby restoring the anti-tumor activity of cytotoxic T lymphocytes. In the specific clinical trial context at Shanghai First Maternity and Infant Hospital, toripalimab is being evaluated in combination with progesterone for the treatment of early-stage endometrial cancer or atypical endometrial hyperplasia in patients seeking fertility preservation. Progesterone, a steroid hormone, acts via the progesterone receptor to induce secretory changes in the endometrium and antagonize estrogen-driven proliferation. This combination therapy aims to improve complete pathological response rates compared to standard hormonal therapy alone, potentially allowing patients to avoid hysterectomy.
- Brand names
- TuoyiLoqtorzi
- Other names
- toripalimab-tpwz
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on toripalimab + progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + progesterone.